SEP 9, 2026 · JOURNAL ARTICLE
Deep and durable response to re-challenge with platinum-based therapy in a platinum-relapsed small cell lung cancer patient following Olvi-Vec oncolytic immunotherapy: a case report
Frontiers in Oncology
A single-case report from an ongoing Phase Ib trial describing one patient's response; while the outcome is noteworthy, case reports lack comparison groups and generalizability to support clinical practice change.
Reported
Target lesion size reduction84.6%
Progression-free survival16.7 months